Assertio Holdings Stock Forecast for 2023 - 2025 - 2030
Updated on 11/29/2023
Assertio Holdings Stock Forecast and Price Target
Assertio Holdings has an average price target of $4.00 recently offered by notable experts for 2023, which would represent a potential upside of approximately 247.83% from the last closing price in November, 2023 if reached. This potential increase is based on a high estimate of $4.00 and a low estimate of $3.50. If you are interested in ASRT stock, it is important to also consider its competitors.
247.83% Upside
Assertio Holdings Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Assertio Holdings's Price has decreased from $5.28 to $0.00 – a 100.00% drop. In the next year, analysts expect Fair Value to reach $0.65 – an increase of 100.00%. For the next eight years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Buy |
17
|
£99.00 | Buy/Sell | £169.00 | 66.17% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$114.49 | Buy/Sell | $0.00 | 72.07% |
| HLUN A Stock Forecast | H. Lundbeck A/S | - |
18
|
kr30.04 | Buy/Sell | kr224.81 | 305.49% |
| INSM Stock Forecast | Insmed | Buy |
11
|
$23.80 | Buy/Sell | $41.42 | 63.87% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Buy |
16
|
$57.13 | Buy/Sell | $71.50 | 22.53% |
Assertio Holdings Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Assertio Holdings's Revenue has decreased from $229.53M to $111.01M – a 51.64% drop. In the next year, analysts expect Revenue to reach $153.63M – an increase of 38.39%. For the next eight years, the forecast is for Revenue to grow by 66.24%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$54.41 | Buy/Sell | $69.00 | 21.30% |
| BHC Stock Forecast | Bausch Health Companies | Outperform |
15
|
$6.86 | Buy/Sell | $34.09 | 16.62% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Outperform |
14
|
$9.68 | Buy/Sell | $17.40 | 106.61% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.97 | Buy/Sell | $41.00 | 53.87% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$27.50 | Buy/Sell | $49.11 | 81.82% |
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$50.32 | Buy/Sell | $71.00 | 39.11% |
Assertio Holdings Free Cash Flow Forecast for 2023 - 2025 - 2030
Assertio Holdings's Free Cash Flow has decreased by 114.62% In the last two years, from $89.00M to $-13.01M. In the following year, the 1 analysts surveyed believe that Assertio Holdings's Free Cash Flow will decrease by 441.35%, reaching $44.41M. According to professionals, by 2030, Assertio Holdings's Free Cash Flow will have decreased by 619.29%, falling down to $67.56M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF38.90 | Buy/Sell | CHF0.00 | 81.90% |
| COLL Stock Forecast | Collegium Pharmaceutical | Outperform |
11
|
$25.50 | Buy/Sell | $33.50 | 31.37% |
| AQST Stock Forecast | Aquestive Therapeutics | Buy |
0
|
$2.13 | Buy/Sell | $0.00 | 205.16% |
Assertio Holdings Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Assertio Holdings's Net Income has decreased from $-217.20M to $-1.28M – a 99.41% drop. For the following year, the 1 analysts predict that Assertio Holdings's Net Income will drop by 1960.16%, reaching $23.81M. In 2030, the professionals' prediction is that ASRT's Net Income will decrease by 3212.41%, reaching $39.84M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABEO Stock Forecast | Abeona Therapeutics | Buy |
8
|
$4.96 | Buy/Sell | $20.50 | 262.90% |
| EBS Stock Forecast | Emergent BioSolutions | Hold |
16
|
$2.01 | Buy/Sell | $5.00 | 148.76% |
| NKTR Stock Forecast | Nektar Therapeutics | Hold |
11
|
$0.42 | Buy/Sell | $29.50 | 554.76% |
Assertio Holdings EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Assertio Holdings's EBITDA has decreased from $97.83M to $49.11M – a 49.80% drop! For next year, analysts predict EBITDA of $80.65M, which would mean an increase of 64.22%. Over the next eight years, experts predict that Assertio Holdings's EBITDA will grow at a rate of 84.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LCI Stock Forecast | Lannett Company | Hold |
10
|
$0.62 | Buy/Sell | $2.25 | 262.90% |
| DRRX Stock Forecast | DURECT | Outperform |
9
|
$0.62 | Buy/Sell | $28.00 | 988.71% |
| ALONX Stock Forecast | Onxeo | Outperform |
8
|
0.35€ | Buy/Sell | 1.26€ | 260.00% |
Assertio Holdings EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Assertio Holdings's EBIT has grown by 492.17%, rising from $-5.11M to $20.04M. For next year, analysts predict EBIT of $36.83M, which would mean an increase of 83.78%. Over the next eight years, experts predict that Assertio Holdings's EBIT will grow at a rate of 185.28%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACOR Stock Forecast | Acorda Therapeutics Inc | - |
5
|
$10.49 | Buy/Sell | $5.00 | -100.00% |
| ENZN Stock Forecast | Enzon Pharmaceuticals | - |
0
|
$0.09 | Buy/Sell | $16.00 | 11.11% |
| ADMP Stock Forecast | Adamis Pharmaceuticals | - |
8
|
$0.33 | Buy/Sell | $1.50 | 9.09% |
Assertio Holdings EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Assertio Holdings's EPS has decreased from $1.88 to $-0.03 – a 101.60% drop. In the following year, 4 experts forecast that Assertio Holdings's EPS will decrease by 866.67%, to $0.23. In 2030, professionals predict that Assertio Holdings's EPS will decrease by 1191.97%, to $0.33.
Site Navigation
.jpg)